New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

Check out this training for the full story!

ALNY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $10,316,756.20

Alnylam Pharmaceuticals Insider Trading History Chart

Alnylam Pharmaceuticals Share Price & Price History

^$171.41

▲ +3.16 (1.88%)

As of 12/1/2023 01:00 AM ET

Days: 30 | 90 | 365

All the trading advice you’ve ever received boils down to this

From DTI Trader | Ad

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

Drop everything and learn about the Income Calendar now.

Alnylam Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2023	Pushkal Garg	CMO	Sell	4,166	$183.89	$766,085.74	4,345
8/4/2023	Jeffrey V. Poulton	CFO	Sell	3,460	$185.85	$643,041.00	15,873
8/4/2023	Pushkal Garg	CMO	Sell	3,461	$185.85	$643,226.85	8,511
8/4/2023	Yvonne Greenstreet	CEO	Sell	4,057	$185.85	$753,993.45	35,216
4/27/2023	Akshay Vaishnaw	President	Sell	2,392	$194.59	$465,459.28	17,890
4/27/2023	Jeffrey V. Poulton	CFO	Sell	977	$194.59	$190,114.43	11,706
4/27/2023	Pushkal Garg	CMO	Sell	1,839	$194.59	$357,851.01	6,800
4/27/2023	Tolga Tanguler	EVP	Sell	1,476	$194.59	$287,214.84	1,801
4/27/2023	Yvonne Greenstreet	CEO	Sell	7,615	$194.59	$1,481,802.85	30,332
4/6/2023	Indrani Lall Franchini	EVP	Sell	3,500	$210.00	$735,000.00
3/3/2023	Pushkal Garg	CMO	Sell	18,072	$200.00	$3,614,400.00	4,345
2/2/2023	Indrani Lall Franchini	EVP	Sell	1,675	$226.01	$378,566.75	3,500
8/5/2022	Tolga Tanguler	EVP	Sell	1,841	$218.16	$401,632.56
8/3/2022	Tolga Tanguler	EVP	Sell	1,754	$210.00	$368,340.00	3,629
7/5/2022	Tolga Tanguler	EVP	Sell	1,754	$150.00	$263,100.00	1,754
4/1/2022	Steven M. Paul	Director	Sell	15,000	$170.69	$2,560,350.00	1,000
12/23/2021	Akshay Vaishnaw	Insider	Sell	2,879	$190.93	$549,687.47
11/12/2021	John Maraganore	CEO	Sell	33,978	$171.52	$5,827,906.56
8/13/2021	John Maraganore	CEO	Sell	33,979	$199.78	$6,788,324.62	248,744
8/6/2021	Yvonne Greenstreet	COO	Sell	53,064	$199.00	$10,559,736.00
8/5/2021	Laurie Keating	EVP	Sell	10,000	$188.95	$1,889,500.00	13,008
7/12/2021	Laurie Keating	EVP	Sell	6,812	$178.96	$1,219,075.52	6,944
6/18/2021	Akshay Vaishnaw	Insider	Sell	14,708	$175.00	$2,573,900.00	24,953
6/9/2021	Laurie Keating	EVP	Sell	1,734	$154.00	$267,036.00	5,132
5/13/2021	John Maraganore	CEO	Sell	33,979	$130.78	$4,443,773.62	248,744
4/21/2021	Akshay Vaishnaw	Insider	Sell	2,732	$136.95	$374,147.40	22,908
4/19/2021	Akshay Vaishnaw	Insider	Sell	3,706	$137.67	$510,205.02	22,908
1/12/2021	Laurie Keating	EVP	Sell	14,941	$160.20	$2,393,548.20	2,234
1/12/2021	Yvonne Greenstreet	COO	Sell	3,125	$161.00	$503,125.00	7,945
12/18/2020	Steven M. Paul	Director	Sell	15,000	$140.00	$2,100,000.00	16,000

New CBOE “special perk” helps traders target income every weekend

From DTI Trader | Ad

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

Check out this training for the full story!

SEC Filings (Institutional Ownership Changes) for Alnylam Pharmaceuticals (NASDAQ:ALNY)

93.98% of Alnylam Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alnylam Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/1/2023	Wellington Management Group LLP	6,431,814	$1.14B	0.2%	+6.0%	5.125%
11/30/2023	American Century Companies Inc.	442,743	$78.41M	0.1%	+0.9%	0.353%
11/27/2023	Banque Pictet & Cie SA	25,424	$4.50M	0.1%	-4.3%	0.020%
11/24/2023	Deutsche Bank AG	462,856	$81.97M	0.1%	-4.9%	0.369%
11/24/2023	EP Wealth Advisors LLC	1,177	$0.21M	0.0%	+6.4%	0.001%
11/22/2023	Graham Capital Management L.P.	1,427	$0.25M	0.0%	-19.3%	0.001%
11/21/2023	Comerica Bank	13,426	$2.38M	0.0%	N/A	0.011%
11/16/2023	Creative Planning	4,121	$0.73M	0.0%	-16.8%	0.003%
11/16/2023	Orion Capital Management LLC	3,675	$0.65M	0.4%	-7.5%	0.003%
11/16/2023	Tudor Investment Corp Et Al	60,004	$10.63M	0.1%	+595.5%	0.048%
11/16/2023	Public Employees Retirement System of Ohio	54,670	$9.68M	0.0%	-9.3%	0.044%
11/15/2023	iA Global Asset Management Inc.	4,174	$0.74M	0.0%	N/A	0.003%
11/15/2023	The Manufacturers Life Insurance Company	355,863	$63.02M	0.0%	+8.9%	0.284%
11/15/2023	Royal London Asset Management Ltd.	306,595	$54.30M	0.2%	+86.7%	0.244%
11/15/2023	Rock Springs Capital Management LP	279,500	$49.50M	1.3%	-19.0%	0.223%
11/15/2023	Schroder Investment Management Group	7,655	$1.36M	0.0%	-6.7%	0.006%
11/15/2023	Sectoral Asset Management Inc.	28,960	$5.13M	1.0%	-2.9%	0.023%
11/15/2023	Legal & General Group Plc	794,671	$140.74M	0.0%	-0.5%	0.633%
11/15/2023	Ameriprise Financial Inc.	706,200	$125.07M	0.0%	+12.9%	0.563%
11/15/2023	Advisors Asset Management Inc.	1,292	$0.23M	0.0%	+40.9%	0.001%
11/15/2023	AQR Capital Management LLC	9,460	$1.66M	0.0%	+65.0%	0.008%
11/14/2023	Lazard Asset Management LLC	15,831	$2.80M	0.0%	+1,585.9%	0.013%
11/14/2023	Schonfeld Strategic Advisors LLC	42,107	$7.46M	0.1%	+1,607.5%	0.034%
11/14/2023	Gotham Asset Management LLC	3,082	$0.55M	0.0%	-20.1%	0.002%
11/14/2023	Corton Capital Inc.	1,338	$0.24M	0.1%	-53.7%	0.001%
11/14/2023	Karani Asset Management LLC	11,555	$2.05M	2.9%	-24.2%	0.009%
11/14/2023	Teza Capital Management LLC	1,318	$0.23M	0.0%	N/A	0.001%
11/14/2023	California State Teachers Retirement System	190,231	$33.69M	0.1%	-4.2%	0.152%
11/14/2023	Toronto Dominion Bank	55,262	$9.79M	0.0%	+79.1%	0.044%
11/14/2023	Bank of Nova Scotia	2,948	$0.52M	0.0%	+18.3%	0.002%
11/14/2023	Tower Research Capital LLC TRC	5,090	$0.90M	0.0%	-46.8%	0.004%
11/14/2023	Qube Research & Technologies Ltd	1,000	$0.18M	0.0%	N/A	0.001%
11/14/2023	Treasurer of the State of North Carolina	85,957	$15.22M	0.1%	-1.1%	0.068%
11/14/2023	Trexquant Investment LP	11,021	$1.95M	0.0%	N/A	0.009%
11/14/2023	MQS Management LLC	1,225	$0.22M	0.1%	N/A	0.001%
11/14/2023	O Shaughnessy Asset Management LLC	1,594	$0.28M	0.0%	+19.3%	0.001%
11/14/2023	OMERS ADMINISTRATION Corp	4,000	$0.71M	0.0%	N/A	0.003%
11/14/2023	Profund Advisors LLC	7,257	$1.29M	0.1%	-6.1%	0.006%
11/13/2023	Eagle Asset Management Inc.	262,680	$46.52M	0.3%	+1.4%	0.209%
11/13/2023	Meiji Yasuda Asset Management Co Ltd.	1,380	$0.24M	0.0%	+13.1%	0.001%
11/13/2023	Northern Trust Corp	797,700	$141.27M	0.0%	+3.3%	0.636%
11/13/2023	Stifel Financial Corp	8,069	$1.43M	0.0%	-13.4%	0.006%
11/13/2023	Mariner LLC	14,181	$2.51M	0.0%	-20.5%	0.011%
11/13/2023	LPL Financial LLC	15,770	$2.79M	0.0%	+6.0%	0.013%
11/13/2023	Acadian Asset Management LLC	904	$0.16M	0.0%	+52.4%	0.001%
11/13/2023	Hsbc Holdings PLC	35,185	$6.23M	0.0%	+14.7%	0.028%
11/13/2023	Bison Wealth LLC	2,553	$0.45M	0.1%	-45.8%	0.002%
11/13/2023	CI Investments Inc.	2,648	$0.47M	0.0%	-11.3%	0.002%
11/13/2023	Envestnet Asset Management Inc.	24,570	$4.35M	0.0%	+30.4%	0.020%
11/13/2023	Nordea Investment Management AB	8,690	$1.53M	0.0%	+3.1%	0.007%
11/13/2023	Envestnet Portfolio Solutions Inc.	1,279	$0.23M	0.0%	N/A	0.001%
11/13/2023	Korea Investment CORP	33,061	$5.86M	0.0%	-15.0%	0.026%
11/13/2023	Rafferty Asset Management LLC	44,168	$7.82M	0.0%	+1.4%	0.035%
11/13/2023	Baillie Gifford & Co.	8,163,139	$1.45B	1.3%	-2.7%	6.505%
11/13/2023	Prudential PLC	4,878	$0.86M	0.0%	-13.5%	0.004%
11/13/2023	ANTIPODES PARTNERS Ltd	111,834	$19.46M	0.6%	+199,603.6%	0.089%
11/13/2023	DekaBank Deutsche Girozentrale	143,100	$24.85M	0.1%	-10.8%	0.114%
11/13/2023	E Fund Management Co. Ltd.	2,271	$0.40M	0.0%	-3.0%	0.002%
11/9/2023	Loomis Sayles & Co. L P	625,401	$110.76M	0.2%	-3.1%	0.498%
11/9/2023	Rhumbline Advisers	172,071	$30.47M	0.0%	-1.9%	0.137%
11/9/2023	Rhenman & Partners Asset Management AB	119,000	$22.90M	1.8%	+164.4%	0.095%
11/9/2023	Deutsche Bank AG	462,856	$81.97M	0.0%	-4.9%	0.369%
11/9/2023	Greenleaf Trust	2,533	$0.45M	0.0%	-3.4%	0.002%
11/9/2023	Skandinaviska Enskilda Banken AB publ	93,225	$16.50M	0.1%	+0.4%	0.074%
11/9/2023	Andra AP fonden	34,500	$6.11M	0.4%	-14.8%	0.027%
11/9/2023	Liontrust Investment Partners LLP	967	$0.17M	0.0%	-91.4%	0.001%
11/9/2023	Headlands Technologies LLC	1,146	$0.20M	0.1%	-57.0%	0.001%
11/9/2023	Mitsubishi UFJ Trust & Banking Corp	386,672	$68.48M	0.2%	-1.7%	0.308%
11/9/2023	Canada Pension Plan Investment Board	151,298	$26.80M	0.0%	-9.7%	0.121%
11/8/2023	State of New Jersey Common Pension Fund D	71,585	$12.68M	0.0%	-3.0%	0.057%
11/8/2023	State Board of Administration of Florida Retirement System	131,210	$23.24M	0.1%	-3.9%	0.105%
11/8/2023	HighTower Advisors LLC	124,439	$22.06M	0.0%	-1.1%	0.100%
11/8/2023	Pathstone Family Office LLC	1,240	$0.22M	0.0%	N/A	0.001%
11/8/2023	Vanguard Personalized Indexing Management LLC	5,735	$1.02M	0.0%	-9.8%	0.005%
11/8/2023	Van ECK Associates Corp	71,086	$12.59M	0.0%	-8.8%	0.057%
11/8/2023	Shell Asset Management Co.	4,832	$0.86M	0.0%	-1.6%	0.004%
11/8/2023	Charles Schwab Investment Management Inc.	418,980	$74.20M	0.0%	+0.7%	0.335%
11/8/2023	Sequoia Financial Advisors LLC	2,803	$0.50M	0.0%	-5.0%	0.002%
11/8/2023	Parnassus Investments LLC	38,748	$6.86M	0.0%	N/A	0.031%
11/8/2023	Massachusetts Financial Services Co. MA	688,228	$121.89M	0.0%	+2.4%	0.551%
11/8/2023	Swiss National Bank	400,600	$70.95M	0.1%	-10.5%	0.320%
11/8/2023	Banque Cantonale Vaudoise	2,058	$0.37M	0.0%	-58.0%	0.002%
11/8/2023	Amalgamated Bank	12,746	$2.26M	0.0%	-3.0%	0.010%
11/8/2023	Moody Aldrich Partners LLC	2,283	$0.40M	0.1%	N/A	0.002%
11/8/2023	New York Life Investment Management LLC	2,226	$0.39M	0.0%	-7.7%	0.002%
11/8/2023	Oppenheimer & Co. Inc.	4,519	$0.80M	0.0%	+2.1%	0.004%
11/7/2023	Great Lakes Advisors LLC	1,445	$0.26M	0.0%	-4.8%	0.001%
11/7/2023	Virtus ETF Advisers LLC	1,533	$0.27M	0.2%	-11.4%	0.001%
11/7/2023	Impax Asset Management Group plc	2,903	$0.51M	0.0%	-5.4%	0.002%
11/7/2023	Clearstead Advisors LLC	4,518	$0.80M	0.0%	+197.6%	0.004%
11/7/2023	Metis Global Partners LLC	4,288	$0.76M	0.0%	+8.7%	0.003%
11/7/2023	Barclays PLC	162,195	$28.73M	0.0%	-22.8%	0.130%
11/7/2023	Arizona State Retirement System	33,973	$6.02M	0.1%	+0.5%	0.027%
11/7/2023	abrdn plc	23,025	$4.08M	0.0%	-2.4%	0.018%
11/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	52,479	$9.29M	0.0%	+12.9%	0.042%
11/7/2023	Segantii Capital Management Ltd	19,250	$3.41M	0.1%	-33.2%	0.015%
11/6/2023	Privium Fund Management B.V.	20,023	$3.55M	1.1%	N/A	0.016%
11/6/2023	Illinois Municipal Retirement Fund	15,644	$2.77M	0.1%	N/A	0.013%
11/6/2023	Assenagon Asset Management S.A.	6,730	$1.19M	0.0%	-92.6%	0.005%
11/6/2023	Sector Gamma AS	52,968	$9.38M	2.4%	+88.7%	0.042%

Data available starting January 2016

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $171.41

$166.02

$171.42

50 Day Range

MA: $166.11

$151.41

$178.96

52 Week Range

Now: $171.41

$148.10

$242.97

Volume

366,015 shs

Average Volume

675,577 shs

Market Capitalization

$21.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Who are the company insiders with the largest holdings of Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' top insider investors include:
Yvonne Greenstreet (CEO)
Akshay Vaishnaw (President)
Jeffrey V Poulton (CFO)
Pushkal Garg (CMO)
Tolga Tanguler (EVP)
Indrani Lall Franchini (EVP)
Steven M Paul (Director)
Akshay Vaishnaw (Insider)
Learn More about top insider investors at Alnylam Pharmaceuticals.
Who are the major institutional investors of Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals' top institutional shareholders include:
Baillie Gifford & Co. — 6.51%
Wellington Management Group LLP — 5.13%
Northern Trust Corp — 0.64%
Legal & General Group Plc — 0.63%
Ameriprise Financial Inc. — 0.56%
Massachusetts Financial Services Co. MA — 0.55%
Learn More about top institutional investors of Alnylam Pharmaceuticals stock.
Which major investors are selling Alnylam Pharmaceuticals stock?: In the last quarter, ALNY stock was sold by these institutional investors:
Baillie Gifford & Co.
Assenagon Asset Management S.A.
Rock Springs Capital Management LP
Barclays PLC
Swiss National Bank
Deutsche Bank AG
Deutsche Bank AG
Loomis Sayles & Co. L P
During the last year, company insiders that have sold Alnylam Pharmaceuticals company stock include:
Yvonne Greenstreet (CEO)
Akshay Vaishnaw (President)
Jeffrey V Poulton (CFO)
Pushkal Garg (CMO)
Tolga Tanguler (EVP)
Indrani Lall Franchini (EVP)
Learn More investors selling Alnylam Pharmaceuticals stock.
Which major investors are buying Alnylam Pharmaceuticals stock?: In the previous quarter, ALNY stock was acquired by institutional investors including:
Wellington Management Group LLP
Royal London Asset Management Ltd.
TD Asset Management Inc
ANTIPODES PARTNERS Ltd
Ameriprise Financial Inc.
Rhenman & Partners Asset Management AB
U.S. Capital Wealth Advisors LLC
Tudor Investment Corp Et Al

All the trading advice you’ve ever received boils down to this

From DTI Trader | Ad

Drop everything and learn about the Income Calendar now.

ALNY Insider Trading

Alnylam Pharmaceuticals Insider Trading History Chart

Alnylam Pharmaceuticals Share Price & Price History

Alnylam Pharmaceuticals Insider Trading History

SEC Filings (Institutional Ownership Changes) for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Institutional Buying and Selling by Quarter

Alnylam Pharmaceuticals Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Alnylam Pharmaceuticals?

Who are the major institutional investors of Alnylam Pharmaceuticals?

Which major investors are selling Alnylam Pharmaceuticals stock?

Which major investors are buying Alnylam Pharmaceuticals stock?